NYSE:BKV
NYSE:BKVOil and Gas

Assessing BKV Corp (BKV) Valuation After Announcing a $100 Million Share Repurchase Program

BKV (BKV) just rolled out a two year, $100 million share repurchase plan, a move that often signals management feels the stock undervalues the business and that it wants more flexibility in capital allocation. See our latest analysis for BKV. That confidence comes after a choppy stretch, with a recent pullback leaving the share price at $26.02 despite a strong 90 day share price return of 21.76 percent and a 1 year total shareholder return of 19.96 percent. This suggests momentum is still...
NYSE:LB
NYSE:LBReal Estate

LandBridge (LB) valuation after new Samsung C&T battery storage partnership on Texas land

LandBridge (LB) just took a clear step into energy storage, signing agreements that give Samsung C&T Renewables exclusive rights to develop two large scale battery projects on its Texas acreage. See our latest analysis for LandBridge. The stock reaction has been cautious so far, with a 1 month share price return of minus 18.63 percent leaving LandBridge at 52.6 dollars. This comes even though its 1 year total shareholder return of minus 9.18 percent and slightly positive 3 month share price...
NYSE:AEM
NYSE:AEMMetals and Mining

Does Agnico Eagle Mines Still Offer Value After a 105% Surge in 2025?

If you are wondering whether Agnico Eagle Mines is still good value after its huge run, you are not alone. This is exactly the question we will unpack. The stock has climbed to around $168.61, delivering an impressive 105.6% year to date and 118.5% over the last year, on top of substantial multi year gains of 243.3% over 3 years and 167.4% over 5 years. Recent market attention has centered on gold prices holding firm near multi year highs and ongoing geopolitical uncertainty, both of which...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

Assessing Monte Rosa Therapeutics (GLUE) Valuation After Encouraging Phase 1/2 Prostate Cancer Trial Results

Monte Rosa Therapeutics (GLUE) just gave investors a fresh catalyst, sharing interim Phase 1/2 data showing 100% disease control and PSA responses in a key prostate cancer subgroup, along with plans for a follow up Phase 2 trial. See our latest analysis for Monte Rosa Therapeutics. That strength in the clinic has gone hand in hand with shifting sentiment in the stock, with a 150.08% 3 month share price return and 128.43% 1 year total shareholder return signaling powerful, still building...
NYSE:BDC
NYSE:BDCElectronic

Will Record Q3 Beat and Software-Led AI Networking Strategy Change Belden's (BDC) Narrative?

Earlier this quarter, Belden reported record third-quarter revenue and adjusted earnings per share, beating analyst expectations and delivering stronger-than-anticipated operating income and Enterprise segment performance. Riverwater Partners’ latest Small Cap Strategy letter emphasized CEO Dr. Ashish Chand’s solutions-focused networking approach and Horizon software platform as key drivers of Belden’s consistent high single-digit revenue growth and double-digit adjusted EPS gains,...
NasdaqGS:WDAY
NasdaqGS:WDAYSoftware

Assessing Workday (WDAY) Valuation After New Compensation and AI Partnership Announcements

Workday (WDAY) is back in the spotlight after unveiling fresh partnerships that deepen its compensation and AI agent ecosystem, moves that matter less for today’s share price and more for its long term platform stickiness. See our latest analysis for Workday. That backdrop of new partnerships lands at a tricky moment for sentiment, with the share price at $218.08 after a soft recent stretch, including a negative year to date share price return and a weaker 1 year total shareholder return,...
NYSE:CNC
NYSE:CNCHealthcare

Does ACA Subsidy Uncertainty Reshape Centene’s Government Programs Story And Prevention Focus (CNC)?

Earlier this week, reports that the House Speaker would not allow a vote on renewing Affordable Care Act premium subsidies raised fresh concerns about Centene’s ACA marketplace exposure and the broader pressure of rising medical costs on health insurers’ profitability. At the same time, Centene’s Ambetter Health and Sunshine Health units have been rolling out community-focused partnerships with professional and elite athletes, highlighting the company’s emphasis on preventive care, Medicaid...
NYSE:VIRT
NYSE:VIRTCapital Markets

Virtu Financial (VIRT): Weighing Long-Term Strength Against Recent Weakness in Today’s Valuation

Virtu Financial (VIRT) has quietly lagged the market this year, even though its longer term returns remain strong. That gap between recent weakness and multi year strength is what makes the stock interesting now. See our latest analysis for Virtu Financial. Over the past year, Virtu’s modest 1 year total shareholder return decline contrasts with its strong three and five year total shareholder returns. This suggests momentum has cooled lately even as the long term story still looks intact at...